Eli Lilly (LLY) Cash from Investing Activities Growth (5y) (2014 - 2026)

Eli Lilly (LLY) Cash from Investing Activities Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,134,969.93 Bn 92,134,964.97 Bn 7.76 Bn
2 Eli Lilly 1,027.45 Bn 1,022.17 Bn 16.22 Bn
3 Johnson & Johnson 559.08 Bn 537.03 Bn 15.96 Bn
4 AbbVie 394.75 Bn 385.40 Bn 10.78 Bn
5 Merck 295.12 Bn 289.47 Bn 12.09 Bn
6 Amgen 186.65 Bn 174.61 Bn 5.87 Bn
7 Gilead Sciences 159.22 Bn 151.50 Bn 5.52 Bn
8 Pfizer 146.00 Bn 133.23 Bn -1.21 Bn
9 Bristol Myers Squibb 113.22 Bn 102.77 Bn 8.07 Bn
10 Novartis Ag 108.02 Bn 107.33 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -24.99%
Dec 31, 2025 -32.97%
Sep 30, 2025 -56.92%
Jun 30, 2025 -54.20%
Mar 31, 2025 -25.88%
Dec 31, 2024 -115.43%
Sep 30, 2024 -56.70%
Jun 30, 2024 -107.04%
Mar 31, 2024 31.27%
Dec 31, 2023 -34.72%
Sep 30, 2023 -50.57%
Jun 30, 2023 -16.51%
Mar 31, 2023 -32.24%
Dec 31, 2022 -20.79%
Sep 30, 2022 11.48%
Jun 30, 2022 18.14%
Mar 31, 2022 6.21%
Dec 31, 2021 16.29%
Sep 30, 2021 4.95%
Jun 30, 2021 13.89%